In a report released yesterday, Vamil Divan from Credit Suisse maintained a Hold rating on Pfizer (PFE), with a price target of $45. The company’s shares closed yesterday at $42.40.
According to TipRanks.com, Divan is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.8% and a 40.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Aimmune Therapeutics, and Johnson & Johnson.
Pfizer has an analyst consensus of Hold, with a price target consensus of $44.78, a 5.6% upside from current levels. In a report issued on December 11, J.P. Morgan also downgraded the stock to Hold with a $46 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.47 and a one-year low of $33.20. Currently, Pfizer has an average volume of 23.28M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
